The CKG not only automatically connected LSD1/KDM1A to tranylcypromine, the drug approved by the tumor board for our patient, but also indicated trans-2-phenylcyclopropylamine, a known potent inhibitor of the demethylase, as another treatment option55. The gene discussed is KDM1A; the disease is neoplasm.